Tedopi Plus Pembrolizumab Improves Survival in Platinum-Resistant Ovarian Cancer with HR of 0.53 in Phase 2 trial.

Novartis presents 2.5-year eGFR data from ALIGN trial of atrasentan in IgA Nephropathy, alongside iptacopan and zigakibart findings in...

LUMA trial of BIIB122 failed to slow Parkinson's disease progression in 648 participants despite confirmed target engagement over 144...

BioCardia's CardiAMP shows 179-second exercise gain in refractory angina trial, with sustained angina reduction over two years of follow-up.

Phesi finds fewer than 1 in 3 trial protocols connect to real patient data — meaning flawed assumptions reach...

Infex's RESP-X Phase IIa bronchiectasis study shows efficacy signal, lung deposition, and clean safety profile supporting Phase IIb/III advancement.

Aktis Oncology reports AKY-2519 dosimetry data showing predicted salivary gland dose of 4.2 Gy RBE, addressing a key toxicity...

TaiMed completes Phase 2b enrollment for TMB-365/380 HIV regimen ahead of schedule, with interim readout expected before end of...

A rare gene therapy-linked cancer case exposes the gap between FDA's 15-year CAR-T surveillance mandate and real-world monitoring systems...

BIIB122 achieved strong target engagement but failed to slow Parkinson's disease progression in the Phase 3 LUMA trial, raising...